Alexion Pharmaceuticals Inc. (ALXN)

117.72
0.58 0.50
NASDAQ : Health Technology
Prev Close 117.14
Open 117.17
Day Low/High 117.17 / 118.20
52 Wk Low/High 96.18 / 149.34
Volume 858.28K
Avg Volume 2.04M
Exchange NASDAQ
Shares Outstanding 222.50M
Market Cap 26.56B
EPS 2.00
P/E Ratio 18.99
Div & Yield N.A. (N.A)

Latest News

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Stay active and selective: These are the five best stocks to invest in right now

Alexion To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference

Alexion To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 2:20 p.

Alexion Reports First Quarter 2018 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

Alexion Reports First Quarter 2018 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the first quarter of 2018.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Alexion Provides Statement On Superior Court Of Justice (STJ) Decision In Brazil Involving Soliris® (Eculizumab)

Alexion Provides Statement On Superior Court Of Justice (STJ) Decision In Brazil Involving Soliris® (Eculizumab)

Recent media reports have incorrectly stated that the Brazilian Superior Court of Justice has granted a compulsory license of Soliris ® (eculizumab).

Three Biotech Names to Consider

Three Biotech Names to Consider

A look at three names to consider in the biotech and biopharma space.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Alexion Pharmaceuticals Moves Up In Analyst Rankings, Passing Philip Morris International

Alexion Pharmaceuticals Moves Up In Analyst Rankings, Passing Philip Morris International

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #21 spot from Philip Morris International Inc , according to ETF Channel.

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the pivotal Phase 3 study of ALXN1210, the Company's investigational long-acting C5 complement inhibitor, demonstrated non-inferiority to Soliris ®...

Alexion To Present At The Cowen And Company 38th Annual Health Care Conference

Alexion To Present At The Cowen And Company 38th Annual Health Care Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 9:20 a.

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

The Manton Center At Boston Children's Hospital And Alexion Pharmaceuticals Partner In Artificial Intelligence Approaches To Rare Disease Diagnosis

The Manton Center At Boston Children's Hospital And Alexion Pharmaceuticals Partner In Artificial Intelligence Approaches To Rare Disease Diagnosis

The Manton Center for Orphan Disease Research, the Innovation and Digital Health Accelerator at Boston Children's Hospital, and Alexion Pharmaceuticals, Inc.

Alexion Reports Fourth Quarter And Full Year 2017 Results And Provides Financial Guidance For 2018

Alexion Reports Fourth Quarter And Full Year 2017 Results And Provides Financial Guidance For 2018

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2017.

Data Presented At WORLDSymposium™ 2018 Show Survival To 3 Years Of Age And Improvements In Liver Function In Infants With Lysosomal Acid Lipase Deficiency Treated With Kanuma® (sebelipase Alfa)

Data Presented At WORLDSymposium™ 2018 Show Survival To 3 Years Of Age And Improvements In Liver Function In Infants With Lysosomal Acid Lipase Deficiency Treated With Kanuma® (sebelipase Alfa)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive...

Alexion Appoints Judith A. Reinsdorf, J.D., To Its Board Of Directors

Alexion Appoints Judith A. Reinsdorf, J.D., To Its Board Of Directors

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Judith A.

Alexion To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Alexion To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Wednesday, February 14, 2018 at 11:00 a.

Alexion Appoints Deborah Dunsire, M.D. To Its Board Of Directors

Alexion Appoints Deborah Dunsire, M.D. To Its Board Of Directors

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Deborah Dunsire, M.

Alexion To Report Fourth Quarter And Full Year 2017 Results On Thursday, February 8, 2018

Alexion To Report Fourth Quarter And Full Year 2017 Results On Thursday, February 8, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2017 on Thursday, February 8, 2018 before the US...

Alexion Pharmaceuticals Moves Up In Analyst Rankings, Passing NRG Energy

Alexion Pharmaceuticals Moves Up In Analyst Rankings, Passing NRG Energy

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #26 spot from NRG Energy Inc , according to ETF Channel.

Alexion And Elliott Agree To Collaborate On Identifying A New Board Member

Alexion And Elliott Agree To Collaborate On Identifying A New Board Member

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) said today that its Board of Directors and Elliott have agreed to work collaboratively to promptly identify a new member to join the Alexion Board.

Alexion To Present At The 36th Annual J.P. Morgan Healthcare Conference

Alexion To Present At The 36th Annual J.P. Morgan Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 36th Annual J.

Soliris® (Eculizumab) Receives Marketing Authorization In Japan For The Treatment Of Patients With Generalized Myasthenia Gravis (gMG)

Soliris® (Eculizumab) Receives Marketing Authorization In Japan For The Treatment Of Patients With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Soliris® (eculizumab) as a treatment for patients with generalized myasthenia...

Alexion To Present At The Goldman Sachs Healthcare CEOs Unscripted Conference

Alexion To Present At The Goldman Sachs Healthcare CEOs Unscripted Conference

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018 at 1:45 p.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting

Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today the presentation of comprehensive dose-ranging data from two Phase 1b/2 studies of ALXN1210, the Company's investigational long-acting C5 complement inhibitor, in...

Stocks Get Boost From Stronger-Than-Expected Jobs Report

Stocks Get Boost From Stronger-Than-Expected Jobs Report

The tech-heavy Nasdaq once again leads the averages higher on Friday.

Stocks Higher After U.S. Adds More Jobs Than Expected in November

Stocks Higher After U.S. Adds More Jobs Than Expected in November

The Nasdaq is once again leading the averages higher on Friday.

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

A report says activist hedge fund Elliott Management wants plans to boost Alexion's share price or it will start a proxy fight for seats on the board.

TheStreet Quant Rating: C (Hold)